news
Lab study questions anti-inflammatory brain benefits of popular supplement CBG
A new laboratory study found cannabigerol produced inconsistent anti-inflammatory responses in brain immune cells and induced strand breaks in isolated DNA across multiple doses. Brands market CBG as a non-intoxicating neuroprotective remedy, but these bench assays suggest its cellular safety profile is far from settled.
A new laboratory study found cannabigerol produced inconsistent anti-inflammatory responses in brain immune cells and induced strand breaks in isolated DNA across multiple doses. Brands market CBG as a non-intoxicating neuroprotective remedy, but these bench assays suggest its cellular safety profile is far from settled.
The architecture take
I lost count of how many wellness founders told me CBG would replace CBD for brain fog and neuro-inflammation. The pitch was simple: the mother cannabinoid, zero high, pure calm for tired microglia (usually priced at thirty dollars a bottle). This new laboratory data from cellular assays tells a much messier story. When researchers exposed cultured brain immune cells to cannabigerol, its suppression of inflammatory cytokines was erratic at best. More concerning was what happened in the DNA cleavage assays, where typical experimental concentrations triggered direct breaks in isolated DNA strands through oxidative activity. Cell cultures aren't human bodies. I'm certainly not panicking over an in vitro dish. Still, the rush to extract minor cannabinoids at high milligram doses has sprinted well past basic toxicology. Brands love selling plant isolates with clinical-sounding promises, yet we don't have pharmacokinetic trials showing what these compounds do to neuronal tissue over six months. I'm keeping CBG off my nightstand until human data catches up.